RGD Reference Report - In vivo anticoagulant effect of ethyl pyruvate in endotoxemic rats. - Rat Genome Database

Send us a Message



Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   

In vivo anticoagulant effect of ethyl pyruvate in endotoxemic rats.

Authors: Kung, CW  Lee, YM  Yen, MH 
Citation: Kung CW, etal., Thromb Res. 2011 Jun;127(6):582-8. Epub 2011 Mar 10.
RGD ID: 5147765
Pubmed: PMID:21396682   (View Abstract at PubMed)
DOI: DOI:10.1016/j.thromres.2011.01.017   (Journal Full-text)

INTRODUCTION: Disseminated intravascular coagulation (DIC), a disorder of the blood coagulation function, is a common complication of severe sepsis. Ethyl pyruvate (EP), a derivative of pyruvate, is known for its anti-inflammatory and antioxidant properties. Recently, EP showed anticoagulant effects in vitro. Therefore, the aim of study is to investigate the in vivo anticoagulant effect of EP on a severe DIC model induced by lipopolysaccharide (LPS) in anesthetized Wistar rats. MATERIALS AND METHODS: The animals were intravenously infused with LPS (30 mg/kg) over a period of 4h. One hour after LPS initiation, rats were treated with EP in three dosages (20, 40 and 60 mg/kg/4h, i.v.). RESULTS: The intermediate and high doses of EP (40 and 60 mg/kg) prevented circulatory failure, improved renal and hepatic function, and reduced the plasma levels of TNF-alpha and IL-6 after LPS administration. All used doses of EP significantly prevented prothrombin time prolongation, and reduced mRNA expression of tissue factor in lung tissue induced by LPS. The two higher doses of EP attenuated plasma concentrations of thrombin-antithrombin complex. The high dose of EP (60 mg/kg) significantly preserved platelet counts, and improved survival rate. However, EP did not reduce the elevation of plasma plasminogen activator inhibitor-1 during endotoxemia. CONCLUSION: EP demonstrates the in vivo anticoagulant effect and improved organ functions in a severe DIC model in rats, which is likely associated with the inhibitory effect on tissue factor mRNA expression and cytokines release. Its effectiveness in preventing DIC is not mediated by increase in fibrinolysis.

RGD Manual Disease Annotations    Click to see Annotation Detail View

Objects Annotated

Genes (Rattus norvegicus)
F2  (coagulation factor II, thrombin)
F3  (coagulation factor III, tissue factor)
Il6  (interleukin 6)
Serpinc1  (serpin family C member 1)
Serpine1  (serpin family E member 1)
Tnf  (tumor necrosis factor)

Genes (Mus musculus)
F2  (coagulation factor II)
F3  (coagulation factor III)
Il6  (interleukin 6)
Serpinc1  (serine (or cysteine) peptidase inhibitor, clade C (antithrombin), member 1)
Serpine1  (serine (or cysteine) peptidase inhibitor, clade E, member 1)
Tnf  (tumor necrosis factor)

Genes (Homo sapiens)
F2  (coagulation factor II, thrombin)
F3  (coagulation factor III, tissue factor)
IL6  (interleukin 6)
SERPINC1  (serpin family C member 1)
SERPINE1  (serpin family E member 1)
TNF  (tumor necrosis factor)


Additional Information